Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14685207 | 0.98 | HSD11B1 (0.60) | HSD11B1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14685202 | 0.95 | HSD11B1 (0.60) | HSD11B1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8776022 | 0.86 | HSD11B1 (0.62) | HSD11B1 | |
| SCHEMBL6777038 | 0.84 | HTR3A (0.58) | HSD11B1 | |
| SCHEMBL2709699 | 0.83 | HTR3A (0.63) | HSD11B1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29689100 | 0.81 | HTR3A (0.62) | HSD11B1MEN1KMT2A | |
| SCHEMBL16649554 | 0.80 | KMT2A (0.68) | KMT2ASMN1; SMN2ALDH1A1NPSR1LMNA | |
| SCHEMBL7427136 | 0.79 | HSD11B1 (0.56) | HSD11B1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4428154 | 0.78 | HSD11B1 (0.58) | HSD11B1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL20919483 | 0.78 | ALDH1A1 (0.50) | MEN1KMT2ASMN1; SMN2ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969345-B2 | Dibenzooxepin derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969345-B2 | Dibenzooxepin derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140163008-A1 | DIBENZOOXEPIN DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| WO-2013018899-A1 | DIBENZOOXEPIN DERIVATIVE | 協和発酵キリン株式会社 (JP) | 2013-02-07 | — | — | WO | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | HSD11B1 2818/4885MEN1 847/4885KMT2A 3751/4885 |
| US-20140163008-A1 | DIBENZOOXEPIN DERIVATIVE | PPARA, PPARG, PPARD | HSD11B1 166/4885MEN1 4518/4885KMT2A 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.